ArticleEpidemiology and infection2022
Carbapenem-resistant
Article in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Coliform Load and Antimicrobial Resistance in Ghana's Seafood Processing Effluent (2021-2024): Evidence of Operational Improvement and Persistent AMR Risk.Life (Basel, Switzerland) · 2026Article
- Genome-wide analysis of extended-spectrum beta-lactamase-producingFrontiers in microbiology · 2026Article
- Detection and Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Raw Seafood From the Coastal Area of Bangladesh.MicrobiologyOpen · 2025Article
- Occurrence, molecular characterization, and antimicrobial susceptibility of sorbitol non-fermenting Escherichia coli in lake water, fish and humans in central Oromia, Ethiopia.Scientific reports · 2024Article
- Genomic surveillance for antimicrobial resistance - a One Health perspective.Nature reviews. Genetics · 2024Review
- Antimicrobial resistance pattern ofPeerJ · 2024Article
- Review
- Extended Spectrum β-Lactamase-Producing Enterobacterales of Shrimp and Salmon Available for Purchase by Consumers in Canada-A Risk Profile Using the Codex Framework.Antibiotics (Basel, Switzerland) · 2023Review
- An overview of carbapenem-resistant organisms from food-producing animals, seafood, aquaculture, companion animals, and wildlife.Frontiers in veterinary science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to carbapenems in human pathogens is a growing clinical and public health concern. The carbapenems are in an antimicrobial class considered last-resort, they are used to treat human infections caused by multidrug-resistant Enterobacterales, and they are classified by the World Health Organization as 'High Priority Critically Important Antimicrobials'. The presence of carbapenem-resistant Enterobacterales (CREs) of animal-origin is of concern because targeted studies of Canadian retail seafood revealed the presence of carbapenem resistance in a small number of Enterobacterales isolates. To further investigate this issue, a risk profile was developed examining shrimp and salmon, the two most important seafood commodities consumed by Canadians and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.